Supporting data for “Establishment of a genetically defined, syngeneic mouse tumor organoid platform for evaluating tumor heterogeneity and response to therapy in liver cancer”.

Hepatocellular Carcinoma (HCC) is a biologically complex and highly heterogeneous disease. As a result of this heterogeneity, the bulk tumor is comprised of a diverse collection of cells harboring distinct molecular signatures with different levels of sensitivity to treatment. To date, treatment for HCC has still followed a traditional “one-size-for-all” strategy where stratification of patients is only based on disease stage; and therapies are often inefficient or ineffective for many individuals. This magnitude of unmet clinical needs suggests that better pre-clinical and translational studies on novel HCC therapies are warranted. One of the key hurdles in working with clinical samples is the difficulty in distinguishing driver from passenger mutations, thus leading to our compromised understanding of pathway dependency of specific driver mutations.

Diver-dependent HCC HTVI models were established with costumed combinations (sgPten/MYC; CTNNB1/MYC; sgTp53/MYC; sgAxin1/MYC; sgKmt2c/MYC and Mcl1/MYC). Mouse mHCC organoids and corresponding tumor tissue are established and characterized derived from the murine HCC models at various OMIC levels.